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Abstract
In our continuing study of curcumin analogs as potential anti-prostate cancer drug candidates, 15
new curcumin analogs were designed, synthesized and evaluated for cytotoxicity against two
human prostate cancer cell lines, androgen-dependent LNCaP and androgen-independent PC-3.
Twelve analogs (5-12, 15, 16, 19, and 20) are conjugates of curcumin (1) or methyl curcumin (2)
with a flutamide- or bicalutamide-like moiety. Two compounds (22 and 23) are C4-mono- and
difluoro-substituted analogs of dimethyl curcumin (DMC, 21). Among the newly synthesized
conjugates compound 15, a conjugate of 2 with a partial bicalutamide moiety, was more potent
than bicalutamide alone and essentially equipotent with 1 and 2 against both prostate tumor cell
lines with IC50 values of 41.8 μM (for LNCaP) and 39.1 μM (for PC-3). A cell morphology study
revealed that the cytotoxicity of curcumin analogs or curcumin-antiandrogen conjugates detected
from both prostate cancer cell lines might be due to the suppression of pseudopodia formation. A
molecular intrinsic fluorescence experiment showed that 1 accumulated mainly in the nuclei,
while conjugate 6 was distributed in the cytosol. At the tested conditions, antiandrogens
suppressed pseudopodia formation in PC-3 cells, but not in LNCaP cells. The evidence suggests
that distinguishable target proteins are involved, resulting in the different outcomes toward
pseudopodia suppression.
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Statistically, prostate cancer is still ranked as the most common cancer in American males
(28%) and was the second leading cause of cancer-related death among men in the United
States (11%) in 2010.2 Constitutive activation of the androgen receptor (AR) by high levels
of androgens is presumed to be responsible for the progression of prostate cancer. Most
presently available chemotherapeutic agents are antiandrogens, including steroidal anti-
androgens and nonsteroidal antiandrogens. The steroidal antiandrogens, such as cyproterone
acetate, possess partial agonistic activity to the AR and inter-activity with other hormonal
systems, which can induce many complications.3-5 The nonsteroidal antiandrogens, such as
flutamide and bicalutamide, have fewer side effects and were thought to be pure AR
antagonists. However, antiandrogen withdrawal syndrome has been discovered in patients
treated with nonsteroidal antiandrogens for several months.6-7 One proposed mechanism for
this syndrome is a mutation of the AR caused by the long-term use of these nonsteroidal
antiandrogens, so that the nonsteroidal antiandrogens exhibit agonistic activity to the mutant
AR.8 Flutamide and bicalutamide (a racemic mixture) (Figure 1) are two well- known
nonsteroidal antiandrogens, widely used for the clinical treatment of prostate cancer.9-10
However, induction of antiandrogen-withdrawal syndrome in patients has been a
considerable problem. Combination usage with a gonadotropin-releasing hormone agonist,
such as goserelin acetate or leuprolide acetate, is currently recommended and used in the
clinic to minimize antiandrogen withdrawal syndrome.11 To date, none of the effective
clinically available antiandrogens is able to kill prostate cancer cells.
Curcumin (1) (Figure 1), a major yellow pigment of Curcuma longa, has been, reported to
have to have anti-prostate cancer activity in vitro and in vivo.12-14 Although the mechanism
of action is still unknown, it has been associated with multiple proteins/signaling pathways,
such as NF-kB,15 STATs,16 AP-1,17 MAPK,18 and Akt,19 etc. More recently, Ras has been
reported to be a potential target protein related to the anticancer activity.20 However, the
metabolic instability of 1 leads to its poor bioavailability, which, in part, prevents 1 from
being used as an efficient therapeutic drug.21-23 Other reports have identified curcumin
analogs that were cytotoxic against androgen-dependent LNCaP cells and androgen-
independent PC-3 cells.24-27 Some analogs demonstrated potent anti-AR activity in LNCaP
cells and PC-3 cells transfected with wild type AR, and were even more potent than
hydroxyflutamide, the active metabolite of flutamide,28-29 although again, the exact
mechanism of action remains unclear.
It is also known that the conjugation of antitumor drugs with other components such as
antioxidants or other antitumor agents has provided some advantages in improving the
antitumor efficacy and selectivity, while decreasing the systematic toxicity.30-32 In our
search for new anti-prostate cancer drugs with increased potency and minimized adverse
antiandrogen effects, we considered conjugation of curcumin or its analogs with clinically
used antiandrogens, such as flutamide and bicalutamide, to be a possible approach to
develop new anti-prostate cancer leads, in addition to the conventional structural
modification of the curcumin molecule alone. Although 1 has been extensively studies
recently in combinations with different cancer therapeutic agents to treat cancers through
synergistic activity,33-34 the conjugation of 1 (or its analog) with a cancer therapeutic agent
has not been explored. Unlike the principle of drug combination, the biological activity of a
conjugate basically results from a single molecule in which two or more active components
are tethered through covalent chemical bonds. The mechanism of action of the conjugate,
therefore, could be different from that of the combination forms. Ideally, the advancement of
the conjugation approach lies in “one molecule double or multiple functions”.35 This field
merits exploration, and in this manner, we hope to develop new drug candidates potentially
inhibiting proliferation of prostate cancer cells and mitigating the side effects of existing
Shi et al. Page 2













antiandrogens. Structurally, flutamide and bicalutamide share a N-(4-substituted-3-
(trifluoromethyl)phenyl)acetamido moiety, which may be an essential pharmacophore for
their anti-prostate cancer activity. New conjugates in which curcumin (1) or methyl
curcumin (2) were coupled with a flutamide molecule (or N-arylmethacrylamide moiety of
bicalutamide) through various linkages were designed and synthesized (Figure 2). The in
vitro anti-prostate cancer activity of the newly synthesized entities was examined and will be
used to guide further optimization of new conjugates. It is also known that an enol-ketone
linkage in 1 (and its analogs) is an important structural feature for its biological activities.25
In order to further confirm this interesting structure-activity phenomenon and the
effectiveness of both enol-ketone/diketone isomers on prostate cancer, we designed and
synthesized compounds 22 and 23, which contain fluorine as an isostere of hydrogen at the
C4 position.36 With the mono-fluoro substitution, we expect that 22 will be stabilized as
only the enol-ketone isomer, while the di-fluoro substituted 23 should retain the diketone
form without tautomerization to an enol-ketone isomer. We also determined the subcellular
distribution of 1 and its conjugate 6 in PC-3 cells by capturing their intrinsic fluorescence,
and observed clear dissimilarity. From these preliminary results, we hope to gain
information not only on new SAR but also regarding promising new anti-prostate cancer
leads and mechanism of action.
2. Results and Discussion
2.1. Chemistry
The starting material 2 was prepared according to a reported synthetic method.37 As
illustrated in Scheme 1, the conjugation of 1 or 2 with flutamide-related analogs, utilized 2-
bromo-2-methyl propanoic acid, which was reacted with 4-substituted-3-
trifluoromethylphenylamines (3a-e) in the presence of EDCI and DMAP to give
corresponding amides (4a-e) in 30-65% yields. Reaction of these amides with 1 or 2 in the
presence of anhydrous cesium carbonate (sodium iodide was used as the catalyst for making
5 and 10) gave the desired compounds 5-12 (2-10% yields) (Scheme 1), along with the
recovered starting materials (1 or 2) (recovery rates: 39%-92%). Various reaction conditions
were tried (such as different bases: Cs2CO3 or K2CO3; solvents: CH3CN, DMF, acetone-
DMF, CH2Cl2 or THF; reaction temperature: rt-80 °C and reaction times: 4 h-overnight) to
improve the yields of the target compounds, but were not successful. The low reaction yields
are probably due to the low reactivity of 4a-4e, resulting from the steric hindrance of
adjacent dimethyl groups. The synthesis of compounds 15 and 16 (Scheme 2) began with the
reaction of methacryloyl chloride with 4-nitro-3-trifluoromethylphenylamine (3a) or 4-
cyano-3-trifluoromethylphenylamine (3b) to afford N-(4-nitro-3-trifluoromethylphenyl)-
methacrylamide (13a) or N-(4-cyano-3-trifluoromethylphenyl)-methacrylamide (13b). The
resulting N-arylmethacrylamides were subsequently oxidized to the corresponding racemic
epoxides (14a and 14b) by using a combination of hydrogen peroxide and trifluoroacetic
anhydride.38 Epoxides 14a and 14b were further reacted with 2 in the presence of sodium
hydride through a ring-opening procedure to afford the target conjugates 15 in 64% yield
and 16 in 41% yield (Scheme 2).
Compounds 19 and 20 were synthesized in three steps beginning from the reaction of
vanillin in DMF with ethyl 4-bromobutyrate in the presence of K2CO3 (for 17a) or with 11-
bromoundercanoic acid in the presence of NaI and Cs2CO3 (for 17b). The vanillin
intermediates 17a and 17b were obtained in yields of 99% and 50%, respectively (Scheme
3). Reaction of these intermediates with 6-(3,4-dimethoxyphenyl)-4-hydroxyhexa-3,5-
dien-2-one25 to afford the corresponding product 18a or 18b was achieved by following a
slightly modified literature procedure.39 Hydrolysis in 10% aq. HCl followed by coupling
with 4-amino-2-(trifluoromethyl)benzonitrile afforded the desired products 19 and 20.
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Compound 22, a C4-mono-fluoro analog, was obtained by fluorination of dimethyl
curcumin (DMC, 21) with SelectFluor™ in DMF. The yield of 22 was relatively low (7%)
due to the difficulty in controlling mono-substitution. Di-fluoro analog 23 was obtained in
the presence of sodium hydride as a major product in 31% yield (Scheme 4).
2.2. Biological Activity and SAR
The newly synthesized analogs were evaluated for cytotoxicity against androgen-dependent
LNCaP and androgen-independent PC-3 human prostate cancer cell lines. The in vitro
cytotoxicity bioassay was performed according to procedures described in literature. 40 The
test compounds were dissolved in DMSO as stock solutions and stored in the dark at −20
°C. The final concentration of DMSO was < 0.5% (v/v) in all experiments. The human
prostate cancer cells were exposed to doses of the compounds for three days. IC50 was
defined as the concentration of test compound causing 50% inhibition of cell growth, as
compared to the untreated control. IC50 values were calculated by log – linear interpolation
of data points. Of the three marketed compounds, 1 was twice as potent as the clinically
used anti-androgens flutamide and bicalutamide against both prostate cancer cell lines in
vitro. The IC50 values for 1 were 36.4 ± 2.4 for LNCaP cell lines and 36.0 ± 1.4 μM for
PC-3 cell lines compared with 81.8 ± 2.1 μM and 98.8 ± 3.2 μM, respectively, for flutamide
and 74.0 ± 5.9 and 76.4 ± 7.2 μM, respectively, for bicalutamide (Table 1).
Among the 12 conjugates, compound 15, a conjugate between 2 and N-[4-nitro-3-
(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide (hydroxyflutamide) exhibited the
most potent cytotoxicity against both cell lines with IC50 values of 41.8 ± 3.9 μM against
LNCaP and 39.1 ± 3.1 μM against PC-3 proliferation. It was essentially equipotent with its
parent compound 2 (IC50 47.0 ± 3.2 μM against LNCaP and 33.1 ± 2.5 μM against PC-3) as
well as 1 and almost twofold more potent than flutamide and bicalutamide (Table 1).
Interestingly, 16, which had only a slight structural variation compared with 15 [the nitro
group (NO2) on the aniline ring of the hydroxyflutamide-related substructure of 15 was
replaced with a cyano group (CN) in 16], was almost twofold less active than 15 against
both cancer cell lines (IC50 73.0 ± 4.2 μM against LNCaP and 100.3 ± 1.9 μM against
PC-3). This result suggests that substitutions in the flutamide portion of the conjugate
molecule can greatly impact the biological activity.
The curcuminoids 1 and 2 were also linked with several 4-substituted-3-
trifluoromethylphenylanilines through an -O-C(CH3)2-CO- amide bond generating
compounds 5-9 and 10-12, respectively. Surprisingly, except for 6 and 7, the anti-prostate
cancer activity was significantly reduced relative to the individual parent compounds (1 or 2
and flutamide). Conjugates 6 and 7, which contain cyano and fluoro groups, respectively, on
the aniline ring in the flutamide substructure, showed significant cytotoxicity against both
prostate cancer cell lines, while conjugates with nitro, chloro, and methyl groups did not.
The results again suggested that the substituents on the flutamide substructure may be
important for interaction of the conjugate molecule with the target protein(s). However, the
curcuminoid portion of the molecule is also important, as conjugate 11, which has the same
cyano-flutamide substructure found in 6, but is conjugated with 2 rather than 1, showed at
least twofold lower cytotoxicity against both LNCaP and PC-3 (IC50 > 100 μM) compared
with 6 or 2, implying that the cytotoxic potency depended on the substituents on both parts
of the conjugate. Even very slight structural deviations (e.g., NO2 vs CN in the flutamide
substructure and OCH3 vs OH in the curcuminoid part) could affect the potency.
The identity of the linker between the curcuminoid phenoxy oxygen and flutamide amido
carbonyl also played a role in the cytotoxic activity. As described above, conjugates 15 and
16 [linker = -CH2C(CH3)(OH)-] showed significant activity, while the corresponding 10 and
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11 [linker = -C(CH3)2-] did not. In addition, conjugates 19 and 20 with unbranched propyl
and decyl linkers, respectively, also did not show significant activity.
The antiproliferation activities induced by the conjugates increased in a dose-dependent
manner. Figures 3 and 4 show dose-dependent curves of the conjugates 6 and 15 on viability
of LNCaP and PC-3 cells compared with bicalutamide and flutamide in RPMI-1640 medium
supplemented in 10% FBS, slightly modified from literature reported methods.41-42 Both
conjugates demonstrate more potent antiproliferation effect than the tested antiandrogens.
Besides the 12 conjugates, two compounds, 22 and 23 were synthesized from dimethyl
curcumin 21 to investigate the role of enol-ketone tautomerism in the anti-prostate cancer
cytotoxicity. Compound 21 was previously synthesized and reported to show anti-prostate
cancer activity.25-26 One of the important structural features contributing to the activity is
the extended unsaturated system resulting from the enol-ketone bridge between the two
phenyl groups. The enol-ketone exists as a stable and predominate tautomer in the
equilibrium with its diketone form. Compound 22, with mono-fluoro substitution at the C4
position, was designed to maximize the enol-ketone form of 21, while compound 23, with a
di-fluoro replacement at C4, was designed to maintain the structure in the diketone form.
Interestingly, compound 22 (IC50 27.3 ± 3.0 μM against LNCaP, 17.7 ± 2.4 μM against
PC-3) was almost as potent as the parent compound 21 and twofold more cytotoxic than its
di-fluoro analog 23 (IC50 53.8 ± 4.9 μM against LNCaP, 44.3 ± 4.8 μM against PC-3),
supporting the postulate that the enol-ketone tautomerism may play a certain role in
inhibition of prostate cancer cell growth in vitro. The physicochemical property of the fluoro
substitution may also affect the potency.
Bicalutamide and flutamide are well known antiandrogens. They inhibit prostate cancer cell
growth through binding to the AR on the prostate and preventing the binding of the natural
ligand. Although it has long been known that 1 and its analogs exhibit anti-prostate cancer
effects, the mechanism behind the biological activity remains unclear. To identify the target
points of cytotoxicity from molecular cell biology level, morphologic changes generated by
active compounds were examined. LNCaP and PC-3 prostate tumor cells were first treated
with 1, 2, and two cytotoxic conjugates, 6 and 15, as well as the antiandrogen bicalutamide.
After incubation with agents for 48 h, the cells were stained with DNA-specific fluorescence
dye DAPI, and the morphologic changes in the cells were analyzed. For LNCaP cells, the
observed cell morphology indicated that 1, 2, and the conjugates strongly inhibited actin-
based pseudopodia formation compared with the control. In contrast, the androgen
antagonist bicalutamide did not suppress the pseudopodia formation in LNCaP cells, even at
a concentration as high as 100 μM (Figure. 5). These observations suggested that 1 and its
analogs, as well as conjugates might share similar mechanism(s) of action in LNCaP
cytotoxicity by inhibiting F-actin formation, not only for the production of pseudopodia, but
also the dynamism of cytoskeletal actin filaments. Interestingly, for PC-3 cells, all tested
compounds, including antiandrogen bicalutamide significantly suppressed pseudopodia-like
extension (Figure 6). In addition, 1 and 2 induced nuclear enlargement, suggesting that
nuclear division and cell cleavage were impaired in PC-3 cells, which might induce cell
cycle arrest at the G2-phase. In contrast to treatment with 1, multinucleated cells were
observed when cells were treated with conjugate 6 or 15 (Figure. 6), indicating that while 1
itself inhibited cell cycle progression,43 the conjugates induced irregular nuclear division
resulting in production of polykaryotic cells that were subject to undergo apoptosis. These
findings led to the hypothesis that 1 and its analogs may target the actin cytoskeletal
dynamics, but it is still unclear whether the irregular nuclear division induced by the
conjugates in PC-3 cells does or does not result from the suppression of F-actin formation.
Such morphologic changes were not observed in the cells treated with the antiandrogen, and
it is also notable that neither flutamide nor bicalutamide showed significant cytotoxicity
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against PC-3 cells within 48 h even at concentration of 100 μM (data not shown), while
suppression of pseudopodia-like formation was observed.
The findings resulting from the current morphology study in LNCaP and PC-3 prostate
cancer cells clearly indicated that different cellular molecules are targets of 1, its analogs,
and conjugates, as well as antiandrogens, though it is still unclear whether the cellular
defects distinguishable between PC-3 and LNCaP are caused by expression of the AR.
Because all test compounds in this study displayed little or no cytotoxic selectivity towards
LNCaP or PC-3 tumor cells, we have speculated that the displayed cytotoxicity might not be
associated completely or at all with androgen or the AR. Nevertheless, because pseudopodia
formation is highly related to cell migration and tumor metastasis,44 1 and its analogs,
including conjugates, may effectively inhibit prostate tumor metastasis. The observed
morphological change induced by the antiandrogens in PC-3 cells may also lead to their
marginal cytotoxicity in a certain degree. Cell invasion assays in the presence of 1-analogs
are currently underway.
The structural uniqueness of 1 and its structural analogs results in detectable molecular
intrinsic fluorescence, which enables us to detect the distribution of the drugs in the cells by
capturing the intrinsic fluorescence under a fluorescence microscope. Experimentally, PC-3
cells were treated with 1 and conjugate 6, respectively, for 1 h (this experiment was not
performed in LNCaP cells due to extremely slow growth), and as expected, the intrinsic
green fluorescence generated by treated compounds was observed in PC-3 cells (Figure. 7).
Interestingly, the intrinsic fluorescence captured from 1-treated cells was accumulated in the
cell nuclei, while for 6 treated cells, intrinsic fluorescence was detected only in the cytosol.
These findings demonstrated a different subcellular distribution between 1 and the conjugate
6. Curcumin distributes and accumulates mainly in the nuclear region, while the conjugate
accumulates mainly in the cytosol.
3. Conclusions
In this study, we designed and synthesized new 1-analogs, including conjugates of 1 (or its
analogs) and antiandrogens (such as flutamide or a substructure of bicalutamide or modified
molecules). The preliminary SAR profile showed that conjugate 15 was equipotent to 1 and
2, and much more potent than flutamide or bicalutamide. Two additional conjugates, 6 and
7, also showed more cytotoxic potency than the clinically used antiandrogens flutamide and
bicalutamide against both androgen-dependent LNCaP and androgen-independent PC-3 cell
lines. These results implied that appropriate accommodation of a large curcuminoid group
on the carbon adjacent to the amide carbonyl of flutamide or bicalutamide may enhance the
inhibition of prostate cancer cells proliferation through different mechanism of action other
than targeting to the AR. Compound 22, a C4 mono-fluorinated curcuminoid, showed
comparable potency to its parent compound 21 and greater potency than its di-fluorinated
analog 23. Morphological and intrinsic fluorescence analysis indicated that 1, its analogs,
and conjugates may target the actin cytoskeletal dynamics in both LNCaP and PC-3 cells. In
PC-3 cells, 1 distributed and accumulated mainly in the nuclei of the cells and inhibited cell
cycle progression by targeting the functional proteins in the nuclear region, while the
conjugates 6 and 15 accumulated mainly in the cytosol and induced irregular nuclear
division, which could lead to prokaryotic cells and eventually apoptosis.
4. Experiments
4.1. Chemistry
Melting points were determined on a Fisher-John melting point apparatus and are
uncorrected. Proton nuclear magnetic resonance (1H NMR) and 13C NMR spectra were
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measured on Varian Gemini 300 or Inova 400 spectrometers with tetramethylsilane (TMS)
as the internal standard. Chemical shifts are reported in δ (ppm). Mass spectra (MS) were
obtained on a Shimadzu LCMS-2010. CombiFlash® chromatographic system (Isco
Companion) with a Grace silica gel cartridge was used for general separation and
purification. Preparative thin layer chromatography (PTLC) on silica gel plates (Kieselgel
60, F254, 1.50 mm) was also used for separation and purification. Precoated silica gel plates
(Kieselgel 60, F254, 0.25 mm) were used for thin layer chromatography (TLC) analysis.
Shimadzu LC-20AT prominence liquid chromatography was used for HPLC. Alltima 2.1
mm × 100 mm C18 3 μm was used as HPLC column. All reagents and solvents were
purchased from Aldrich, Fisher, VWR, and other venders. Some chemicals were used after
purification, and others were used as purchased. Compounds 1, 2, and 21 were synthesized
by following literature methods.25-26 All final compounds are >95% pure through HPLC
analysis.
4.2. Synthesis of 2-bromo-2-methyl-N-(4-substituted-3-(trifluoromethyl)-
phenylpropanamides (4a-e)
4.2.1. General procedure—2-Bromo-2-methylpropionic acid (1.5 equiv), EDCI (1.5 or 2
equiv) and DMAP (1.5 or 2 equiv) were added to a solution of 4-substituted-3-
(trifluoromethyl)aniline in CH2Cl2 (for 3a,b,c,e) or pyridine (for 3d), and the mixture was
stirred at 35 °C overnight (60 °C, 4 h for pyridine as solvent) under N2. The mixture was
diluted with CH2Cl2, washed with sat. NH4Cl (aq.), sat. NaHCO3 (aq.), and brine, then dried
over anhydrous MgSO4. After removal of the solvent in vacuo, the crude products were
purified by silica gel column chromatography eluting with n-hexane-EtOAc.
4.2.2. 2-Bromo-N-(4-nitro-3-(trifluoromethyl)phenyl)-2-methylpropanamide (4a)
—Yield: 12%, white solid powder; 1H NMR (300 MHz, CDCl3): δ 2.06 (s, 3H, CH3), 2.07
(s, 3H, CH3), 7.98 (s, 1H, aromatic-H), 7.99 (s, 1H, aromatic-H), 8.06 (s, 1H, aromatic-H),
ESI MS m/z 355.98 (M+H)+.
4.2.3. 2-Bromo-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methylpropanamide
(4b)—Yield: 64%; white solid; mp. 168-170 °C; 1H NMR (400 MHz, CDCl3): δ 1.90 (3H,
s, CH3), 2.06 (3H, s, CH3), 7.82 (1H, d, J = 8.6 Hz, Ar-H), 7.95 (1H, dt, J = 8.6, 2.1 Hz, Ar-
H), 8.11 (1H, dd, J = 6.6, 1.9 Hz, Ar-H), 8.80 (br, 1H, NH). ESI-MS (negative, m/z): 333.05
[M-H]-, 335.00 [M+2-H]-.
4.2.4. 2-Bromo-N-(4-fluoro-3-(trifluoromethyl)phenyl)-2-methylpropanamide
(4c)—Yield: 64%; white solid; mp. 111-112 °C; 1H NMR (400 MHz, CDCl3): δ 1.89 (3H,
s, CH3), 2.06 (3H, s, CH3), 7.20 (1H, t, J = 9.3 Hz, Ar-H), 7.73-7.75 (1H, m, Ar-H), 7.84
(1H, td, J = 9.0, 2.7 Hz, Ar-H), 8.52 (br, 1H, NH). ESI-MS (negative, m/z): 325.95 [M-H]-,
328.00 [M+2-H]+.
4.2.5. 2-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)-2-methylpropanamide
(4d)—Yield: 29%; white solid; mp. 134-135°C; 1H NMR (400 MHz, CDCl3): δ 2.05 (6H, s,
CH3), 7.48 (1H, d, J = 8.8 Hz, Ar-H), 7.73 (1H, dd, J = 8.8, 2.5 Hz, Ar-H), 7.91 (1H, d, J =
2.5 Hz, Ar-H), 8.54 (br, 1H, NH). ESI-MS (negative, m/z): 342.05 [M-H]-, 344.05 [M+2-
H]-, 345.95 [M+4-H]-.
4.2.6. 2-Bromo-N-(4-methyl-3-(trifluoromethyl)phenyl)-2-methylpropanamide
(4e)—Yield: 49%; white solid; mp. 125-126°C; 1H NMR (400 MHz, CDCl3): δ 2.05 (6H, s,
CH3), 2.46 (3H, s, Ar-CH3), 7.27 (1H, d, J = 8.2 Hz, Ar-H), 7.64 (1H, dd, J = 8.2, 2.1 Hz,
Ar-H), 7.78 (1H, d, J = 2.1 Hz, Ar-H), 8.48 (br, 1H, NH). ESI-MS (negative, m/z): 322.15
[M-H]-, 324.00 [M+2-H]-.
Shi et al. Page 7













4.3. Synthesis of N-(4-substituted-3-(trifluoromethyl)phenyl)pivalamide-curcumin or
methylcurcumin analogs (5-12)
4.3.1 General procedure—Compounds 4a-4e (1.1, 1.5 or 3.0 equiv) and Cs2CO3 (1.5
equiv) were added to a solution of 1 or 2 in CH3CN, and the mixture was stirred at 60 °C for
3 h, 5 h or overnight under N2. The mixture was quenched with 0.1N HCl to pH 6 and
extracted three times with EtOAc. The combined organic layers were washed with H2O and
brine. After being dried over anhydrous Na2SO4, the solvent was removed in vacuo. The
crude products were purified by CombiFlash® column chromatography or preparative-TLC
eluting with n-hexane-EtOAc.
4.3.2. N-(4-Nitro-3-(trifluoromethyl)phenyl)pivalamide-curcumin (5)—Yield:
10%; amorphous solid; 1H NMR (300 MHz, DMSO-d6): δ 8.49 (s, 1H), 8.36-8.32 (m 1H),
8.24-8.21 (m, 1H), 7.58-7.53 (m, 2H), 7.42 (br s, 1H), 7.32 (br s, 1H), 7.26-7.14 (m, 2H),
6.96-6.89 (m, 2H), 6.84-6.56 (m, 2H), 6.09 (s, 1H), 3.84 (s, 3H, OCH3), 3.81 (s, 3H, OCH3),
1.53 (s, 6H, CH3); ESI MS m/z 643.13 (M+H)+.
4.3.3. N-(4-Cyano-3-(trifluoromethyl)phenyl)pivalamide-curcumin (6)—Yield: 5%
(starting with 0.26 mmol of curcumin), amorphous solid; 1H NMR (400 MHz, CDCl3): δ
1.58 (6H, s, CH3), 3.95 and 3.96 (each 3H, s, OCH3), 5.83 (1H, s, C=CH), 6.50 and 6.56
(each 1H, d, J = 15.8 Hz, CH=CH), 6.94 (1H, d, J = 8.2 Hz, Ar-H), 7.06 (1H, d, J = 1.7 Hz,
Ar-H), 7.08 (1H, d, J = 8.0 Hz, Ar-H), 7.136 (1H, dd, J = 8.2, 1.7 Hz, Ar-H), 7.141 (1H, d, J
= 1.9 Hz, Ar-H), 7.17 (1H, dd, J = 8.4, 1.9 Hz, Ar-H), 7.61 and 7.62 (each 1H, d, J = 15.8
Hz, CH=CH), 7.83 (1H, d, J = 8.4 Hz, Ar-H’), 8.03 (1H, dd, J = 8.4, 2.1 Hz, Ar-H’), 8.09
(1H, d, J = 1.9 Hz, Ar-H’), 10.02 (1H, s). ESI-MS (positive or negative, m/z): 623.50 [M
+H]+, 621.30 [M-H]-.
4.3.4. N-(4-Fluoro -3-(trifluoromethyl)phenyl)pivalamide-curcumin (7)—Yield:
6% (starting with 0.27 mmol of curcumin), amorphous solid; 1H NMR 400 MHz, CDCl3): δ
1.58 (6H, s, CH3), 3.95 (6H, s, OCH3), 5.83 (1H, s, C=CH), 6.49 and 6.55 (each 1H, d, J =
15.8 Hz, CH=CH), 6.94 (1H, d, J = 8.2 Hz, Ar-H), 7.05 (1H, s, Ar-H), 7.07 (1H, d, J = 8.6
Hz, Ar-H), 7.13 (1H, s, Ar-H), 7.16 (2H, d, J = 8.2 Hz, Ar-H), 7.61 and 7.62 (each 1H, d, J =
15.8 Hz, CH=CH), 7.75 (1H, d, J = 8.6 Hz, Ar-H’), 7.87 (1H, d, J = 8.6 Hz, Ar-H’), 7.90
(1H, s, Ar-H’), 9.68 (1H, s). ESI-MS (positive or negative, m/z): 616.25 [M+H]+, 614.40
[M-H]-.
4.3.5. N-(4-Chloro-3-(trifluoromethyl)phenyl)pivalamide-curcumin (8)—Yield:
6% (starting with 0.33 mmol of curcumin), yellow solid; mp. 268-270 °C, 1H NMR (400
MHz, CDCl3): δ 1.58 (6H, s, CH3), 3.95 and 3.96 (each 3H, s, OCH3), 5.83 (1H, s, C=CH),
6.50 and 6.55 (each 1H, d, J = 15.8 Hz, CH=CH), 6.94 (1H, d, J = 8.2 Hz, Ar-H), 7.06 (1H,
d, J = 1.9 Hz, Ar-H), 7.07 (1H, d, J = 8.2 Hz, Ar-H), 7.13 (1H, d, J = 1.9 Hz, Ar-H), 7.14
(1H, dd, J = 8.6, 1.9 Hz, Ar-H), 7.16 (1H, dd, J = 8.4 1.9 Hz, Ar-H), 7.49 (1H, d, J = 8.7 Hz,
Ar-H’), 7.61 and 7.62 (1H, d, J = 15.8 Hz, CH=CH), 7.88 (1H, dd, J = 8.6, 2.5 Hz, Ar-H’),
7.96 (1H, d, J = 2.5 Hz, Ar-H’), 9.74 (1H, s). ESI-MS (positive or negative, m/z): 632.10 [M
+H]+, 634.25 [M+2+H]+, 630.35 [M-H]-, 632.35 [M+2-H]-.
4.3.6. N-(4-Methyl-3-(trifluoromethyl)phenyl)pivalamide-curcumin (9)—Yield:
2% (starting with 0.27 mmol of 1), amorphous solid; 1H NMR (400 MHz, CDCl3): δ 1.58
(6H, s, CH3), 2.46 (3H, s, Ar-CH3), 3.80 and 3.95 (each 3H, s, OCH3), 5.85 (1H, s, C=CH),
6.56 and 6.57 (each 1H, d, J = 15.8 Hz, CH=CH), 6.77 (1H, dd, J = 8.4, 2.5 Hz, Ar-H), 6.88
(1H, d, J = 8.0 Hz, Ar-H), 6.97 (1H, d, J = 2.3 Hz, Ar-H), 7.07 (1H, d, J = 8.2 Hz, Ar-H),
7.08 (1H, s, Ar-H), 7.15 (1H, d, J = 8.0 Hz, Ar-H), 7.28 (1H, d, J = 8.7 Hz, Ar-H’), 7.61 and
Shi et al. Page 8













7.63 (each 1H, d, J = 15.8 Hz, CH=CH), 7.80 (1H, d, J = 8.4 Hz, Ar-H’), 7.83 (1H, s, Ar-
H’), 9.61 (1H, s). ESI-MS (positive or negative, m/z): 612.25 [M+H]+, 610.15 [M-H]-.
4.3.7. N-(4-Nitro-3-(trifluoromethyl)phenyl)pivalamide-methylcurcumin (10)—
Yield: 3%; amorphous solid; 1H NMR (300 MHz, acetone-d6): δ 8.55 (s, 1H), 8.32 (s, br,
1H), 8.18-8.20 (m, 1H), 7.66-7.61 (m, 2H), 7.46 (br s, 1H), 7.39-7.14 (m, 4H), 7.00-7.03 (m,
1H), 6.86-6.73 (m, 2H), 6.03 (s, 1H), 3.98 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.87 (s, 3H,
OCH3), 1.57 (s, 6H, CH3); ESI MS m/z 657.3 (M+H)+.
4.3.8 N-(4-Cyano-3-(trifluoromethyl)phenyl)pivalamide-methylcurcumin (11)—
Yield: 5% (starting with 0.13 mmol of methylcurcumin), amorphous solid; 1H NMR (400
MHz, CDCl3): δ 1.79 (6H, s, CH3), 3.80, 3.93 and 3.94 (each 3H, s, OCH3), 4.96 (1H, s),
5.84 (1H, s, C=CH), 6.51 and 6.55 (each 1H, d, J = 16.0 Hz, CH=CH), 6.79 (1H, dd, J = 8.4,
2.3 Hz, Ar-H’), 6.89 (1H, d, J = 8.4 Hz, Ar-H), 6.90 (1H, d, J = 8.0 Hz, Ar-H), 6.96 (1H, d, J
= 2.3 Hz, Ar-H’), 7.08 (1H, d, J = 1.7 Hz, Ar-H), 7.10 (1H, s, Ar-H), 7.14 (1H, dd, J = 8.0,
1.7 Hz, Ar-H), 7.15 (1H, dd, J = 8.2, 1.7 Hz, Ar-H), 7.59 and 7.63 (each 1H, d, J = 15.8 Hz,
CH=CH), 7.61 (1H, d, J = 8.6 Hz, Ar-H’). ESI-MS (positive, m/z): 637.30 [M+H]+.
4.3.9. N-(4-Chloro-3-(trifluoromethyl)phenyl)pivalamide-methylcurcumin (12)—
Yield: 3% (starting with 0.26 mmol of methylcurcumin), amorphous solid; 1H NMR (400
MHz, CDCl3): δ 1.72 (6H, s, CH3), 3.78, 3.91 and 3.92 (each 3H, s, OCH3), 4.36 (1H, s),
5.82 (1H, s, C=CH), 6.49 and 6.53 (each 1H, d, J = 15.6 Hz, CH=CH), 6.75 (1H, dd, J = 8.7,
2.7 Hz, Ar-H’), 6.87 (2H, d, J = 8.2 Hz, Ar-H), 6.98 (1H, d, J = 2.7 Hz, Ar-H’), 7.067 (1H,
s, Ar-H), 7.074 (1H, s, Ar-H’), 7.11 (1H, dd, J = 8.0, 1.7 Hz, Ar-H), 7.13 (1H, dd, J = 8.0,
1.7 Hz, Ar-H’), 7.27 (1H, d, J = 8.7 Hz, Ar-H’), 7.57 and 7.61 (each 1H, d, J = 15.6 Hz,
CH=CH). ESI-MS (positive, m/z): 646.15 [M+H]+.
4.4. Synthesis of N-(4-substituted-3-(trifluoromethyl)phenyl) methacrylamide (14a,b): N-(4-
substituted-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide-methylcurcumin
(15-16)
4.4.1. General procedure—Methacryloyl chloride (1.2-3.0 eq.) was added dropwise to a
solution of 4-nitro-3-trifluoromethylphenylamine (3a) or 4-cyano-3-
trifluoromethylphenylamine (3b) in CH2Cl2 containing triethylamine (1.2-3.0 eq.) at 0 °C.
After stirring at room temperature for 4-12 h with TLC monitoring, the reaction mixture was
diluted with CH2Cl2 and washed with H2O. The CH2Cl2 extract was then dried over
Na2SO4, concentrated, and purified by flash column chromatography to afford the desired
compounds.
4.4.2. N-(4-Nitro-3-trifluoromethylphenyl)methacrylamide (13a)—Yield: 41%;
amorphous solid; 1H NMR (300 MHz, CDCl3): δ 1.98 (s, 3H, CH3), 5.70 (s, 1H, ethylene-
H), 5.79 (s, 1H, ethylene-H), 8.38-8.17 (m, 3H, aromatic-H); ESI MS m/z 274.2 (M+H)+.
4.4.3. N-(4-Cyano-3-trifluoromethylphenyl)methacrylamide (13b)—Yield: 20%;
amorphous solid; 1H NMR (300 MHz, CDCl3): δ 2.08 (s, 3H, CH3), 5.60 (s, 1H, ethylene-
H), 5.86 (s, 1H, ethylene-H), 8.05-7.78 (m, 3H, aromatic-H); ESI MS m/z 254.2 [M+H]+.
4.5. Synthesis of N-(4-substituted-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-
carboxamide (14a,b)
4.5.1. General procedure—To a solution of N-arylmethacrylamides (13a or 13b, 1.7
mmol) in CH2Cl2 (25 mL) was added 0.31 mL of hydrogen peroxide (30%, w/w) followed
by 1.25 mL of trifluoroacetic anhydride. After stirring at rt for 2 h, the reaction was
quenched by addition of sodium bisulfide and extracted with CH2Cl2. The organic layer was
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washed with sat. NaHCO3 then brine, and dried over MgSO4. After removal of the solvent
by evaporation, the crude was purified through a CombiFlash® chromatograph system to
afford the desired products as racemic epoxides.
4.5.2. N-(4-Nitro-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide
(14a)—Yield: 81%; pale-yellow powder; 1H NMR (300 MHz, CDCl3) δ 1.70 (s, 3H, CH3).
3.04 (s, 2H, epoxide-H), 7.23 (s, 1H, NH), 7.82 (d, 1H, J = 8.7 Hz, aromatic-H),8.17 (d, 1H,
J = 8.7 Hz, aromatic-H), 8.23 (s, 1H, aromatic-H); ESI MS m/z 291.7 [M+H]+.
4.5.3. N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide
(14b)—Yield: 70%; white powder; 1H NMR (300 MHz, CDCl3) δ 1.68 (s, 3H, CH3), 3.01
(s, 2H, epoxide-H), 7.78 (d, 1H, J = 8.7 Hz, aromatic-H),7.91 (dd, 1H, J = 2.4, 8.7 Hz,
aromatic-H), 8.03 (d, J = 2.1 Hz, 1H, aromatic-H), 8.42 (s, 1H, NH); ESI MS m/z 292.7 [M
+Na]+.
4.6. Synthesis of N-(4-substituted-3-(trifluoromethyl)phenyl)-2-hydroxy-2-
methylpropanamide-methylcurcumin (15, 16)
4.6.1 General procedure—Methylcurcumin (2) (0.26 mmol in 3 mL of THF) was cooled
to 0 °C. Sodium hydride (60%) (0.37 mmol) was added. After stirring at rt for 5 min, 14a or
14b (0.27 mmol) was added. The resulting mixture was heated to reflux for 24 h. The
reaction mixture was diluted with CH2Cl2 and washed with water twice and extracted with
CH2Cl2. After purification through a Combiflash® system, the desired product was obtained.
4.6.2. N-(4-Nitro-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamido-
methylcurcumin (15)—Yield: 64%; amorphous solid; 1H NMR (400 MHz, CDCl3): δ
1.57 (s, 3H, CH3), 3.92-3.91 (m, 9H, OCH3), 3.96 (d, J = 9.6 Hz, 1H), 4.46 (d, J = 9.6 Hz,
1H), 5.81 (s, 1H), 6.49 (dd, J = 15.6, 1.2 Hz, 2H), 6.87 (d, J = 8.4 Hz, 1H), 7.06 (s, 2H), 7.13
(dd, J = 8.4, 1.6 Hz, 2H), 7.60 (d, J = 16.0 Hz, 1H), 7.62-7.54 (m, 1H), 7.95 (d, J = 8.4 Hz,
1H), 8.00-7.97 (m, 2H), 8.07 (dd, J = 8.8, 2.0 Hz, 1H), 9.30 (s, 1H,), 8.52 (s, 1H); 13C NMR
(400 MHz, CDCl3): δ 20.6 (CH3); 56.2 (OCH3 x 3), 75.1 (CH2), 84.9 [-C(OH)CH3CO],
101.6 (COCH=COH), 122.4 (CF3), 110..0, 111.0, 111.4, 116.2, 118.2, 122.1, 122.4, 123.4,
127.3 (aromatic CH), 120.5 (CHOHCH=CH), 139.7 (-CH=CH-Ph), 122.9 (COCH=CH-Ph),
141.0 (COCH=CH-Ph), 128.1, 128.2, 130.6, 141.9, 143.4 (aromatic C), 149.0, 149.5, 150.0,
151.4 (aromatic C-OCH3); 173.5 (-CONH-), 182.6 (enol COCHCOH), 184.2 (carbonyl CO-
CH=COH); ESI MS m/z 656.2 [M+H]+.
4.6.3. N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide-
methylcurcumin (16)—Yield:41%; amorphous solid; 1H NMR (300 MHz, acetone-d6): δ
1.56 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.16 (d, J =
9.6 Hz, 1H), 4.42 (d, J = 9.6 Hz, 1H), 6.00 (s, 1H), 6.74 (d, J = 15.6 Hz, 2H), 7.02 (d, J =
15.9 Hz, 1H), 7.05 (d, J = 15.9 Hz, 1H), 7.23 (t, J = 13.8, 7.2 Hz, 2H), 7.31 (d, J = 4.8 Hz,
2H), 7.59 (d, J = 15.9 Hz, 1H), 7.62 (d, J = 15.9 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 8.31 (d, J
= 8.7 Hz, 1H), 8.52 (s, 1H), 10.03 (s, 1H,); ESI MS m/z 653.4 [M+H]+.
4.7. Ethyl 4-(4-formyl-2-methoxyphenoxy)butanoate (17a)
To a solution of vanillin (1.0 g, 6.6 mmol) in DMF (20 mL), ethyl 4- bromobutyrate (2.8
mL, 19.6 mmol) and K2CO3 (360 mg, 9.8 mmol) were added and the mixture was stirred at
80 °C for 2 days under N2. The mixture was quenched with 0.1N HCl to pH 6 and extracted
three times with EtOAc. The combined organic layer was washed with H2O and brine, and
then dried over anhydrous MgSO4, and the solvent was removed in vacuo. The crude was
purified by CombiFlash® column chromatography eluting with n-hexane-EtOAc gradient to
give the desired compound (1.7 g, 99%), white solid; mp. 75-76°C; 1H NMR (400 MHz,
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CDCl3): δ 1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 2.20 (2H, quintet, J = 6.8 Hz,
OCH2CH2CH2CO), 2.55 (2H, t, J = 7.2 Hz, OCH2CH2CH2CO), 3.92 (3H, s, OCH3), 4.15
(2H, q, J = 7.2 Hz, OCH2CH3), 4.17 (2H, t, J = 6.4 Hz, OCH2CH2CH2CO), 6.99 (1H, d, J =
8.2 Hz, Ar-H), 7.41 (1H, d, J = 1.7 Hz, Ar-H), 7.44 (1H, dd, J = 8.2, 1.7 Hz, Ar-H), 9.85
(1H, s, CHO). ESI-MS (positive, m/z): 267.05 [M+H]+, 289.00 [M+Na]+.
4.7.1. 4-(4-Formyl-2-methoxyphenoxy)undecanoic acid (17b)—Compound 17b
was synthesized using a similar procedure to that of making 17a with slight modification. To
a solution of vanillin (502 mg, 3.3 mmol) in DMF-dioxane (3: 1, 20 mL), 11-
bromoundecanoic acid (2.6 g, 9.9 mmol), NaI (2.5 g, 16.4 mmol) and Cs2CO3 (2.1 g, 6.6
mmol) were added and the mixture was stirred at 100 °C for 4 days under N2. The workup
and purification steps were as described above from 17a. to give 17b (552 mg, 50%) as an
amorphous solid; 1H NMR (400 MHz, CDCl3): δ 1.55-1.59 (2H, m, CH2), 1.58-1.63 (12H,
m, CH2), 1.88 (2H, quintet, J = 7.6 Hz, CH2CH2CH2), 2.29 (2H, t, J = 7.6 Hz, CH2CH2CO),
3.93 (3H, s, OCH3), 4.06 (2H, t, J = 6.6 Hz, OCH2CH2), 6.97 (1H, d, J = 8.0 Hz, Ar-H),
7.41 (1H, s, Ar-H), 7.44 (1H, d, J = 8.4 Hz, Ar-H), 9.85 (1H, s, CHO). ESI-MS (negative, m/
z): 335.10 [M-H]-.
4.8. O-Butanoic acid substituted methylcurcumin (18a)
To a solution of 6-(3,4-dimethoxyphenyl)-4-hydroxyhexa-3,5-dien-2-one25 (837 mg, 3.1
mmol) in EtOAc (8 mL) was added boric anhydride (171 mg, 2.5 mmol). The solution was
stirred at 70 °C for 1 h. To this solution were added 17a (1247 mg, 4.7 mmol) and tributyl
borate (1.3 mL, 4.8 mmol). The mixture was stirred for 0.5 h and a solution of n-butylamine
(0.46 mL, 4.7 mmol) in EtOAc (4 mL) was added dropwise over 15 min at 85 °C. The
stirring was continued for 3 h at 100 °C. The mixture was then hydrolyzed by adding 0.1 N
HCl and stirred at 50°C for 0.5 h. The organic layer was separated, and the aqueous layer
was extracted with EtOAc. The combined organic layers were washed H2O and brine and
dried over anhydrous Na2SO4. After removal of solvent in vacuo, the crude products were
purified by CombiFlash® column chromatography eluting with n-hexane-EtOAc gradient to
give the ethyl ester precursor of 18a (393 mg, 25%), amorphous solid, 1H NMR (400 MHz,
CDCl3): δ 1.26 (3H, t, J = 7.2 Hz, OCH2CH3), 2.17 (2H, quintet, J = 6.8 Hz, OCH2-CH2-
CH2-CO), 2.54 (2H, t, J = 7.0 Hz, OCH2-CH2-CH2-CO), 3.91, 3.92 and 3.93 (each 3H, s,
OCH3), 4.11 (2H, t, J = 6.2 Hz, OCH2-CH2-CH2-CO), 4.15 (2H, q, J = 7.0 Hz, OCH2CH3),
5.82 (1H, s, C=CH), 6.49 and 6.50 (each 1H, d, J = 15.6 Hz, CH=CH), 6.878 (1H, d, J = 8.2
Hz, Ar-H), 6.883 (1H, d, J = 8.4 Hz, Ar-H), 7.07 (2H, s, Ar-H), 7.13 (2H, t, J = 8.4 Hz, Ar-
H), 7.59 and 7.60 (each 1H, d, J = 15.6 Hz, CH=CH). ESI-MS (positive or negative, m/z):
497.20 [M+H]+, 495.10 [M-H]-.
To a solution of resulting compound (393 mg, 0.79 mmol) in THF (10 mL) was added 10%
HCl (6 mL) and then the solution was stirred at 70 °C overnight. To the mixture was added
H2O (20 mL) and extracted with EtOAc. The organic layer was washed with H2O and brine
and dried over anhydrous Na2SO4. After removal of the solvent in vacuo, the crude was
purified by CombiFlash® column chromatography eluting with n-hexane-EtOAc gradient to
afford 18a (263 mg, 71%), amorphous solid, 1H NMR (400 MHz, CDCl3): δ 2.19 (2H,
quintet, J = 6.8 Hz, OCH2-CH2-CH2-CO), 2.63 (2H, t, J = 7.0 Hz, OCH2-CH2-CH2-CO),
3.91, 3.93 and 3.94 (each 3H, s, OCH3), 4.13 (2H, t, J = 6.2 Hz, OCH2-CH2-CH2-CO), 5.82
(1H, s, C=CH), 6.50 (2H, d, J = 15.8 Hz, CH=CH), 6.89 (2H, d, J = 8.4 Hz, Ar-H), 7.08 (2H,
s, Ar-H), 7.14 (2H, t, J = 8.2 Hz, Ar-H), 7.60 and 7.61 (each 1H, d, J = 15.6 Hz, CH=CH).
ESI-MS (positive or negative, m/z): 469.10 [M+H]+, 467.15 [M-H]-.
A similar procedure was used to prepare 18b.
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4.8.1. O-Undecanoic acid substituted methylcurcumin (18b)—Yield: 25%;
amorphous solid, 1H-NMR (400 MHz, CDCl3): δ 1.45-146 (2H, m, CH2), 1.61-163 (12H,
m, CH2), 1.86 (2H, quintet, J = 7.6 Hz, CH2), 2.29 (2H, t, J = 7.6 Hz, CH2), 3.92, 3.93 and
3.94 (each 3H, s, OCH3), 4.05 (2H, t, J = 6.6 Hz, OCH2), 5.82 (1H, s, C=CH), 6.49 (1H, d, J
= 15.8 Hz, CH=CH), 6.50 (1H, d, J = 15.6 Hz, CH=CH), 6.87 and 6.89 (each 1H, d, J = 8.4
Hz, Ar-H), 7.08 (2H, s, Ar-H), 7.13 (1H, d, J = 8.2 Hz, Ar-H), 7.15 (1H, d, J = 8.4 Hz, Ar-
H), 7.61 (2H, d, J = 15.8 Hz, CH=CH). ESI-MS (negative, m/z): 565.35 [M-H]-.
4.9. N-(4-Cyano-3-(trifluoromethyl)phenyl)butyramide-methylcurcumin (19)
4-Amino-2-(trifluoromethyl)benzonitrile (97 mg, 0.52 mmol), EDCI (100 mg, 0.52 mmol)
and DMAP (63 mg, 0.52 mmol) were added to a solution of 18a (120 mg, 0.26 mmol) in
CH2Cl2 (8 mL), and the mixture was stirred at 35°C overnight under N2. The mixture was
diluted with CH2Cl2 and then washed with sat. NH4Cl (aq.), sat. NaHCO3 (aq.), and brine,
then dried over anhydrous Na2SO4. After removal of the solvent in vacuo, the product was
purified by CombiFlash® column chromatography eluting with n-hexane-EtOAc gradient to
give the desired 19 (60 mg, 37%), amorphous solid, 1H NMR (400 MHz, CDCl3): δ 2.27
(2H, quintet, J = 6.8 Hz, OCH2-CH2-CH2- CO), 2.68 (2H, t, J = 7.0 Hz, OCH2-CH2-CH2-
CO), 3.84, 3.92 and 3.93 (each 3H, s, OCH3), 4.17 (2H, t, J = 5.8 Hz, OCH2-CH2-CH2-CO),
5.82 (1H, s, C=CH), 6.49 and 6.50 (each 1H, d, J = 15.8 Hz, CH=CH), 6.88 and 6.90 (each
1H, d, J = 8.4 Hz, Ar-H), 7.075 and 7.080 (each 1H, d, J = 2.1 Hz, Ar-H), 7.12 and 7.14
(each 1H, dd, J = 8.4, 1.7 Hz, Ar-H), 7.58 and 7.61 (each 1H, d, J = 15.8 Hz, CH=CH), 7.75
(1H, d, J = 8.4 Hz, Ar-H’), 7.95 (1H, s, Ar-H’), 7.97 (1H, dd, J = 8.4, 1.9 Hz, Ar-H’), 8.62
(1H, s, NH). ESI-MS (positive, m/z): 637.40 [M+H]+.
4.9.1. N-(4-Cyano-3-(trifluoromethyl)phenyl)undecanamide - methylcurcumin
(20)—A similar procedure to that described above for 19 gave the desired product 20 (46
mg, 15%), amorphous solid, 1H NMR (400 MHz, CDCl3): δ 1.43-1.45 (2H, m, CH2),
1.61-1.68 (10H, m, CH2), 1.72-1.76 (2H, m, CH2), 1.83-1.86 (2H, m, CH2), 2.29 (2H, t, J =
7.2 Hz, CH2CO), 3.91, 3.93 and 3.94 (each 3H, s, OCH3), 4.05 (2H, t, J = 6.4 Hz, OCH2),
5.83 (1H, s, C=CH), 6.49 and 6.50 (each 1H, d, J = 15.8 Hz, CH=CH), 6.88 (1H, d, J = 8.2
Hz, Ar-H), 6.89 (1H, d, J = 8.4 Hz, Ar-H), 7.08 (2H, s, Ar-H), 7.12 (1H, d, J = 8.9 Hz, Ar-
H), 7.14 (1H, d, J = 8.4 Hz, Ar-H), 7.61 (2H, d, J = 15.8 Hz, CH=CH), 7.76 (1H, d, J = 8.4
Hz, Ar-H’), 7.96 (1H, d, J = 8.4 Hz, Ar-H’), 8.00 (1H, s, Ar-H’). ESI-MS (positive, m/z):
735.50 [M+H]+
4.10. 4-Fluoro substituted dimethylcurcumin (22)
Dimethylcurcumin (21) (198 mg, 0.5 mmol) in DMF (5 mL) was added to SelectFluor™
(0.51 mmol). The mixture was stirred at rt overnight under N2. The solvent was removed by
distillation and the remaining solid was dissolved in CH2Cl2 and washed with water. After
being dried over Na2SO4 the crude product was purified by flash column eluting by n-
hexane: EtOAc = 6: 1 to afford the desired product 22 as an orange powder in 7% yield. 1H
NMR (300 MHz, CDCl3): δ 3.94-3.92 (m, 12H, OCH3) 6.88 (d, J = 8.4 Hz, 2H), 6.98 (dd, J
= 15.9, 3.0 Hz, 2H), 7.12-7.11 (m, 2H), 7.21 (dd, J = 8.4, 1.8 Hz, 2H), 7.65 (d, J = 15.9 Hz,
2H),; ESI MS m/z 413.2 [M-H]-, 437.2 [M+Na]+.
4.11. 4,4-Difluoro substituted dimethylcurcumin (23)
A solution of dimethylcurcumin (21) (80 mg, 0.2 mmol) in THF (5 mL) was added to a
suspension of 10 mg of NaH (80% in mineral oil) at 0 °C. The mixture was stirred at 0 °C
for 0.5 h, then rt for 1h. A solution of SelectFluor™ (80 mg, 0.22 mmol) in DMF (2 mL)
was then added and the mixture was stirred for additional 8 h. After additional 30 mg of
SelectFluor™ in DMF (1 mL) was added, the reaction mixture was continually stirred for
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0.5 h. The solvent was removed by distillation and the remained solid was purified by flash
column chromatography (eluting by n-hexane: EtOAc = 6: 1) and PTLC (n-hexane: EtOAc
= 1: 2) to give the desired product 23 (27 mg, 31% yield) as yellow solid powder. 1H NMR
(300 MHz, CDCl3): δ 3.92 (s, 12H, OCH3), 6.87 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 15.6 Hz,
2H), 7.11 (d, J = 2.1 Hz, 2H), 7.21 (dd, J = 8.4, 2.1 Hz, 2H), 7.48 (d, J = 15.6 Hz, 2H); ESI
MS m/z 433.2 [M+H]+, 455.1 [M+Na]+.
4.12. Cell culture
PC-3 (ATCC CRL 1435) and LNCaP clone FGC (ATCC CRL 1740) cell lines were
obtained from Lineberger Comprehensive Cancer Center (UNC-CH). PC-3 cells were
cultured in RPMI-1640 medium containing 25 mM HEPES and 2 mM L-glutamine
(Mediatech), supplemented with 10% heat-inactivated fetal bovine serum (Hyclone), 100 IU
penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B (Mediatech). In
addition, 1 mM sodium pyruvate (Mediatech) was added to the medium for LNCaP cells.
Cells were incubated in 5 % CO2 and 95% air at 37 °C.
4.13. Antiproliferative activity assay
Antiproliferative activity was determined by the sulforhodamine B (SRB) colorimetric assay
as previously described.45 In brief, the cells (3-5 × 103 cells/well) were seeded in 96-well
plates filled with RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS)
containing various concentrations of samples, and incubated for 72 h. At the end of the
exposure period, the attached cells were fixed with cold 50% trichloroacetic acid for 30 min
followed by staining with 0.04% SRB (Sigma Chemical Co.) for 30 min. The bound SRB
was solubilized in 10 mM Tris-base and the absorbance was measured at 515 nm on a
Microplate Reader ELx800 (Bio-Tek Instruments, Winooski, VT) with a Gen5 software. All
results were representative of three or more experiments.
4.14. Morphological analysis and intrinsic fluorescence of compounds in cells
PC-3 and LNCaP tumor cells were maintained in RPMI-1640 medium supplemented with
10% FBS in 8-well chamber slides (Lab-Tech) for 12 h prior to treatment with DMSO, 1 (30
μM), 2 (40 μM), 6 (50 μM), 15 (40 μM), and flutamide (100 μM), or bicalutamide (100
μM) for 48 h at 37 °C. For intrinsic fluorescence analysis, PC-3 cells were treated with 40
μM compound for 1 h at 37 °C. Cells were fixed with 4% paraformaldehyde in phosphate
buffered saline (PBS). Nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI,
Sigma), and cells were mounted with VECTASHIELD (vector labs). Fluorescence labeled
cells were observed using a Nikon ECLLIPSE E400 fluorescence microscope and images
were captured by a SPOT cooled digital camera controlled by the SPOT Software
(Diagnostic Instruments Inc.). Final images were prepared using Adobe Photoshop ver 6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of flutamide, hydroxyflutamide, bicalutamide, and curcumin
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Design of curcumin analogs conjugated with hydroxyflutamide or bicalutamide moiety.
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Dose-response curves of conjugates and antiandrogens in LNCaP cells. Cells were cultured
in RPMI-1640 medium supplemented with 10% FBS in the presence of compound for 72 h.
All data were calculated as the mean ± SE of triplicate samples and are representative of at
least three individual experiments.
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Dose-response curves of conjugates and antiandrogens in PC-3 cells. Cells were cultured in
RPMI-1640 medium supplemented with 10% FBS in the presence of compound for 72 h.
All data were calculated as the mean ± SE of triplicate samples and are representative of at
least three individual experiments.
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Suppression of pseudopodia formation in LNCaP cells by curcumin analogs. Androgen-
sensitive LNCaP cells were cultured for 48 h in RPMI-1640 medium supplemented with
10% FBS in the presence of compound. Cells were fixed and stained with DAPI for DNA.
Vigorous pseudopodia formation was seen in untreated (DMSO) or 100 μM bicalutamide-
treated cells (arrows), while pseudopodia formation was limited in cells treated with 6 or 15,
and completely impaired in cells treated with 1 or 2. These observations implied that
curcumin and its analogs strongly inhibited pseudopodia formation in LNCaP cells. Bar, 50
μm.
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Induction of nuclear fragmentation in PC-3 cells by curcumin analogs. Androgen-
independent PC-3 cells were treated with compound as indicated for 48 h followed by
staining with DAPI for DNA. PC-3 cells treated with 1 or 2 often showed nuclear
enlargement (black arrows), suggesting that PC-3 cells induced cell cycle arrest at G2/M.
Interestingly, when PC-3 cells were treated with 6 or 15, polykaryocytes (multinucleated
cells) (arrow heads) were frequently observed. In addition, pseudopodia- like extension
(white arrow) was not seen in agent-treated cells. Bar, 50 μm.
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Figure 7. Subcellular distribution of curcumin (1) and conjugate 6 in PC-3 cells
PC-3 cells were briefly treated with 1 or 6. The intrinsic fluorescence of compound was
observed under the fluorescence microscope (left panels, green). DAPI was used for staining
nuclei (center panels, red), and merged with intrinsic fluorescence (right panels). The
intrinsic fluorescence of 1 or 6 was detected and showed subcellular distribution of these
compounds in PC-3 cells. Bar, 50 μm.
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Synthesis of conjugates 5-12
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Synthesis of conjugates 15 and 16
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Synthesis of conjugates 19 and 20
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Synthesis of conjugates 22 and 23
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Table 1
Cytotoxicity data for curcumin and curcumin analogs against LNCaP and PC-3 human prostate cancer cell
lines.
a
IC50 ± SE (μM)
Compound LNCaP PC-3
Curcumin (1) 36.4 ± 2.4 36.0 ± 1.4
Bicalutamide 74.0 ± 5.9 76.4 ± 7.2
Flutamide 81.8 ± 2.1 98.8 ± 3.2
2 47.0 ± 3.2 33.1 ± 2.5
5 > 100 > 100
6 55.0 ± 4.1 48.1 ± 4.6
7 54.8 ± 2.5 52.1 ± 4.8
8 > 100 > 100
9 > 100 > 100
10 > 100 > 100
11 > 100 > 100
12 > 100 > 100
15 41.8 ± 3.9 39.1 ± 3.1
16 73.0 ± 4.2 100.3 ± 1.9
19 96.3 ± 8.3 > 100
20 > 100 > 100
21 15.3 ± 2.8 23.7 ± 1.4
22 27.3 ± 3.0 17.7 ± 2.4
23 53.8 ± 4.9 44.3 ± 4.8
a
Cell proliferation was determined by SRB assay as described in “Antiproliferative Activity Assay”. Data are expressed as the means ± SE of at
least three or more independent experiments
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